Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $14,486.04 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 526 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,486.04. Following the completion of the transaction, the chief executive officer now directly owns 1,048,729 shares in the company, valued at approximately $28,881,996.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total transaction of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $27.53 on Friday. The company has a 50-day moving average price of $23.21 and a 200-day moving average price of $21.97. The stock has a market capitalization of $1.29 billion, a P/E ratio of -14.26 and a beta of 1.09. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its stake in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after purchasing an additional 37,632 shares in the last quarter. First Turn Management LLC bought a new stake in Enliven Therapeutics in the 2nd quarter worth about $9,657,000. American Century Companies Inc. increased its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after buying an additional 8,540 shares during the last quarter. Finally, Nicholas Investment Partners LP bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, Robert W. Baird began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.